XML 36 R27.htm IDEA: XBRL DOCUMENT v3.21.2

Other Operating Income and Expense (Tables)

6 Months Ended

Jun. 30, 2021

Other Operating Income and Expense

Schedule of other operating income and expense

​

​	​	​	​	​	​	​	​	​
​		H1 2021		H1 2020		FY 2020		FY 2019
​	​	$m	​	$m	​	$m	​	$m
Divestment of Viela Bio, Inc. shareholding	​	776	​	-	​	-	​	-
Crestor (Europe ex-UK and Spain)	​	309	​	-	​	-	​	-
Oxra and Oxramet (India)	​	40	​	-	​	-	​	-
Hypertension medicines (ex-US, India and Japan)	​	-	​	350	​	350	​	-
Monetisation of an asset previously licensed	​	-	​	-	​	120	​	-
Brazikumab licence termination funding	​	51	​	-	​	107	​	-
Inderal, Tenormin, Seloken and Omepral (Japan)	​	-	​	51	​	51	​	-
Synagis (US)	​	-	​	-	​	-	​	515
Losec (ex-China, Japan, US and Mexico)	​	-	​	-	​	-	​	243
Seroquel and Seroquel XR (US, Canada, Europe and Russia)	​	-	​	-	​	-	​	213
Arimidex and Casodex (various countries)	​	-	​	-	​	-	​	181
Nexium (Europe) and Vimovo (ex-US)	​	-	​	-	​	54	​	-
Atacand	​	-	​	-	​	400	​	-
Other	​	132	​	200	​	446	​	389
Total	​	1,308	​	601	​	1,528	​	1,541

X

- Definition

The disclosure of other operating income or expense.

+ References

No definition available.

+ Details

Name:	azn_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock
Namespace Prefix:	azn_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_ProfitLossAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration